Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series

被引:23
作者
Kerkemeyer, Karolina L. [1 ]
Meah, Nekma [1 ]
Sinclair, Rodney D. [1 ]
机构
[1] Sinclair Dermatol, East Melbourne, Vic, Australia
关键词
D O I
10.1016/j.jaad.2020.10.016
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
[No abstract available]
引用
收藏
页码:581 / 583
页数:3
相关论文
共 5 条
[1]   Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare [J].
Damsky, William ;
Thakral, Durga ;
McGeary, Meaghan K. ;
Leventhal, Jonathan ;
Galan, Anjela ;
King, Brett .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (03) :612-621
[2]   Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis [J].
Damsky, William ;
Thakral, Durga ;
Emeagwali, Nkiruka ;
Galan, Anjela ;
King, Brett .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) :2540-2546
[3]   Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument [J].
Noe, Megan H. ;
Gelfand, Joel M. ;
Bryer, Joshua S. ;
Price, Sarah N. ;
Judson, Marc A. ;
Rosenbach, Misha .
JAMA DERMATOLOGY, 2020, 156 (01) :98-99
[4]   Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia [J].
Rotenberg, Cecile ;
Besnard, Valerie ;
Brillet, Pierre-Yves ;
Giraudier, Stephane ;
Nunes, Hilario ;
Valeyre, Dominique .
EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (06)
[5]  
Wei Jenny J, 2019, JAAD Case Rep, V5, P360, DOI 10.1016/j.jdcr.2019.02.006